AZD1208_1204144-28-4_MSDS_MedChemExpress
沙库巴曲缬沙坦联合达格列净对2_型糖尿病肾病患者的疗效分析
·糖尿病与并发症·糖尿病新世界 2024年2月DOI：10.16658/ki.1672-4062.2024.03.185沙库巴曲缬沙坦联合达格列净对2型糖尿病肾病患者的疗效分析李海东江苏如东洋口医院肾内科，江苏如东226407[摘要]目的探讨2型糖尿病肾病（Diabetic Nephropathy, DN）患者治疗中合用沙库巴曲缬沙坦与达格列净的临床疗效和对肾功能指标的影响。
方法选取2022年1月—2023年1月如东洋口医院收治的68例2型DN患者为研究对象，采用随机数表法分为对照组和观察组，每组34例。
对照组予以达格列净单一治疗，观察组予以达格列净和沙库巴曲缬沙坦联合治疗。
比较两组的临床疗效、肾功能指标、血糖变化及氧化应激指标。
结果观察组治疗总有效率高于对照组，差异有统计学意义（P<0.05）。
治疗后，两组空腹血糖、糖化血红蛋白水平均呈下降趋势，且观察组下降更明显，差异有统计学意义（P均<0.05）。
治疗后，两组尿素氮、血肌酐、24 h尿蛋白定量均呈下降趋势，肾小球滤过率呈升高趋势，且观察组改变更明显，差异有统计学意义（P均< 0.05）。
治疗后，两组总抗氧化能力、超氧化物歧化酶、谷胱甘肽过氧化物酶呈升高趋势，且观察组升高幅度更大，差异有统计学意义（P均<0.05）。
结论合用沙布巴曲缬沙坦与达格列净，在2型DN患者治疗中可取得确切疗效，改善肾功能，并实现血糖的良好控制，减轻炎症反应，提高预后。
[关键词] 沙库巴曲缬沙坦；达格列净；2型糖尿病；肾病；肾功能[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062（2024）02（a）-0185-05Efficacy of Sacubactril Valsartan Combined with Dapagliflozin in Patients with Type 2 Diabetic NephropathyLI HaidongDepartment of Nephrology, Yangkou Hospital, Rudong, Jiangsu Province, 226407 China[Abstract] Objective To investigate the clinical efficacy and effect of sacubactril valsartan and dapagliflozin on renal function in patients with type 2 diabetic nephropathy (DN). Methods 68 patients with type 2 DN admitted to Yangkou Hospital of Rudong from January 2022 to January 2023 were selected as the study objects and were divided into con⁃trol group and observation group by random number table method, with 34 cases in each group. The control group was given single treatment of daglipzin, and the observation group was given combined treatment of daglipzin and sakuba⁃tril valsartan. The clinical effects, and renal function indexes, blood glucose changes, and oxidative stress indexes of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, fasting plasma glucose (FPG) and glyeosylated hemoglobin A1c (HbA1c) in both groups decreased, and the increase were more significant in the ob⁃servation group, and the difference was statistically significant (all P<0.05). After treatment, blood urea nitrogen (BUN), serum creatinine (Scr) and 24-hour urinary protein quantity (24 hUTP) in both groups showed a decreasing trend, the glomerular filtration rate showed an increasing trend, and the change was more obvious in the observation group, and the difference was statistically significant (all P<0.05). After treatment, total antioxidant capacity (T-AOC), superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) in both groups showed an increasing trend, and the [作者简介]李海东（1976-），男，本科，主任医师，研究方向为肾小球肾炎、糖尿病肾病。
2019多黏菌素国际共识指南解读
CMS与多黏菌素B排泄途径
多黏菌素B主要通过非肾脏途径排泄
Nation RL, et al. Clin Infect Dis 2014;59:88–94.
Andrea Kwa, et al. Expert Rev. Anti Infect. Ther. 5(5), 811–821 (2007) Yiying Cai, et al. Expert Rev. Anti Infect. Ther. 13(12), 1481–1497 (2015)
PK/PD参数：fAUC/MIC
Bergen PJ, et al. Antimicrob Agents Chemother 2010;9:3783–9.
对于CMS全身给药，推荐目标血浆colistin平均稳态浓度Css,avg为2mg/L，是基于以 下几点考虑：
1. 考虑到动物和人体血蛋白结合率的差异，人体血浆蛋白结合率约为50%；
2019多黏菌素国际共识指南解读
多黏菌素优化使用国际共识指南
◆ American College of Clinical Pharmacy (ACCP)：美国临床药学协会 ◆ European Society of Clinical Microbiology and Infectious Diseases (ESCMID)：欧洲临床微生物和感染病学会 ◆ Infectious Diseases Society of America (IDSA)：美国感染病学会 ◆ International Society for Anti-infective Pharmacology (ISAP)：国际抗 感染药理学会 ◆ Society of Critical Care Medicine (SCCM)：美国重症医学会 ◆ Society of Infectious Diseases Pharmacists (SIDP)：感染病药师学会
不同亚型CHO_宿主细胞对抗体表达的影响
生物技术进展 2023 年 第 13 卷 第 5 期 698 ~ 703Current Biotechnology ISSN 2095‑2341进展评述Reviews不同亚型CHO 宿主细胞对抗体表达的影响曹辉 ， 董静 ， 贾宇 ， 江一帆*华北制药集团新药研究开发有限责任公司，抗体药物河北省工程研究中心，抗体药物研究国家重点实验室，石家庄 050015摘要：CHO 细胞作为宿主细胞广泛应用于生物药工业化生产中。
其中，CHO -K1、CHO -DG44和CHO -S 是最常见的3种亚型。
虽然这些亚型是从共同的原始CHO 细胞分离出来的，但在不同的实验室或生物医药公司、研究人员、培养基或培养方式下连续传代、驯化和保存，使得CHO 细胞积累了大量变异，导致宿主细胞应用于抗体药生产时会在细胞生长状态、抗体表达量及以糖型为代表的质量属性方面表现出较大差异。
综述了CHO 细胞不同亚型的染色体差异、生长状态、表达差异以及糖型差异，以期为抗体药物研发中宿主细胞的选择提供参考。
关键词：CHO 细胞；抗体；表达量；糖型DOI ：10.19586/j.2095‑2341.2023.0064中图分类号：Q28, R392-33 文献标志码：AEffects of Different Sources of CHO Host Cells on Antibody ExpressionCAO Hui ， DONG Jing ， JIA Yu ， JIANG Yifan *State Key Laboratory of Antibody Drug Development ， Hebei Engineering Research Center of Antibody Medicine ， New Drug Research and Development Co. Ltd ， North China Pharmaceutical Corporation ， Shijiazhuang 050015， ChinaAbstract ：CHO cells comprise a variety of lineages including CHO -K1， CHO -DG44 and CHO -S ， which have been widely used in the industrial production of biological drugs. All CHO cell lines share a common ancestor ， however ， during the process of cell passage cultivation ， cell domesticated ， and preservation by different laboratories or companies ， substantial genetic heterogeneity among them has been produced ， that showed great differences in cell growth state ， antibody titer ， glycosylation and other product quality attributes. This article reviewed the difference in chromosome ， growing status and expression ， and glycoform in different sources ofCHO host cells ， which was expected to be helpful in host cell selection during antibody drug research and development process.Key words ：CHO cells ； monoclonal antibody ； antibody titer ； glycosylation生物药物在国际医药市场中占据主导地位，截至2023年，全球范围内已有100多个抗体药物被批准上市，近1 200个抗体药物处于不同临床试验阶段［1］。
盐酸多巴酚丁胺-安全技术说明书MSDS
第一部分化学品及企业标识化学品中文名：盐酸多巴酚丁胺化学品英文名：4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]pyrocatechol hydrochloride CAS No.：49745-95-1分子式：C18H24ClNO3产品推荐及限制用途：工业及科研用途。
第二部分危险性概述紧急情况概述吞咽有害。
皮肤接触有害。
吸入有害。
怀疑对生育能力或胎儿造成伤害。
GHS危险性类别急性经口毒性类别 4急性经皮肤毒性类别 4急性吸入毒性类别 4生殖毒性类别 2标签要素：象形图：警示词：警告危险性说明：H302 吞咽有害H312 皮肤接触有害H332 吸入有害H361 怀疑对生育能力或胎儿造成伤害●预防措施：—— P264 作业后彻底清洗。
—— P270 使用本产品时不要进食、饮水或吸烟。
—— P280 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
—— P261 避免吸入粉尘/烟/气体/烟雾/蒸气/喷雾。
—— P271 只能在室外或通风良好处使用。
—— P201 使用前取得专用说明。
—— P202 在阅读并明了所有安全措施前切勿搬动。
●事故响应：—— P301+P312 如误吞咽：如感觉不适，呼叫解毒中心/ 医生—— P330 漱口。
—— P302+P352 如皮肤沾染：用水充分清洗。
—— P312 如感觉不适，呼叫解毒中心/医生—— P362+P364 脱掉沾染的衣服，清洗后方可重新使用—— P304+P340 如误吸入：将人转移到空气新鲜处，保持呼吸舒适体位。
—— P308+P313 如接触到或有疑虑：求医/就诊。
●安全储存：—— P403+P233 存放在通风良好的地方。
保持容器密闭。
—— P405 存放处须加锁。
●废弃处置：—— P501 按当地法规处置内装物/容器。
物理和化学危险：无资料。
健康危害：吞咽有害。
皮肤接触有害。
吸入有害。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Toceranib_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jun.-08-2017Print Date:Jun.-08-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :ToceranibCatalog No. :HY-10330CAS No. :356068-94-51.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:SU 11654; PHA 291639; SU11654; SU–11654; PHA–291639; PHA291639Formula:C22H25FN4O2Molecular Weight:396.46CAS No. :356068-94-54. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
GC测定盐酸普拉克索中三乙胺残留量
泛昔洛韦
密度：1.4g/cm3 熔点：102-104°C 沸 点 ： 5 5 0 . 2 ºC 闪 点 ： 2 8 6 . 6 ºC 折射率：1.628 外观：灰白色粉末 溶解性：易溶于丙酮或甲醇，难溶于乙醇或异丙醇
摩尔折射率：82.66 摩尔体积（cm3/mol）：239.8 等张比容（90.2K）：639.3 表面张力（dyne/cm）：50.4 极化率（10-24cm3）：32.77
进入人体内后迅速转变成喷昔洛韦，喷昔洛韦可被病毒编码的胸苷激酶磷酸化成OCV单磷酸，再经宿主的磷 酸化成为喷昔洛韦三磷酸盐，三磷酸盐在病毒感染的细胞内迅速形成，缓慢代谢，致半衰期延长，参与HBV DNAp的三磷酸鸟苷(Pgtp)竞争，并进入DNA，作用于DNA合成的起始和延伸步骤，抑制DNA的合成，对水痘-带状疱疹 病毒、单纯疱疹病毒1型和2型和HBV均有较强的抑制作用。
泛昔洛韦
药品
目录
01 化合物简介
03 药典信息
02 药品简介 04 安全信息
泛昔洛韦，是一种有机化合物，化学式为C14H19N5O4，是第二代开环核苷类抗病毒药，主要用于疱疹病毒感 染，尤其是带状疱疹。
化合物简介
基本信息 理化性质
分子数据 化学数据
化学式：C14H19N5O4 分子量：321.332 CAS号：-87-4
疏水参数计算参考值（XlogP）：无 氢键供体数量：1 氢键受体数量：8 可旋转化学键数量：9 互变异构体数量：3 拓扑分子极性表面积：122 重原子数量：23 表面电荷：0 复杂度：404 同位素原子数量：0 确定原子立构中心数量：0
药品简介
作用机理
药代动力学
不良反应
泛昔洛韦口服迅速吸收，生物利用度77%，在体内很快转达变为喷昔洛韦，t1/2约为2h，约60-65%经肾排出。 在水痘-带状疱疹病毒感染的细胞内有一个较长的半衰期（9-10小时），单纯疱疹病毒1型和2型感染的细胞内半 衰期分别为10小时和20小时。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Version 2.1 Revision Date: 07/08/2013
Print Date: 12/05/2013
MSDS
1 Composition
7 Accident Release Measure
Product Name:AZD1208
Chemical Name:
PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavy
rubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and
wash spill site after material pickup is complete.
2,4-Thiazolidinedione, 5-[[2-[(3R)-3-amino-1-piperidinyl][1,1'-biphenyl]-3-yl]methylene]-, (5Z)-
CAS No.:1204144-28-4
8 Accident Release Measure
Appearance:light yellow to yellow(Solid)Formula:C21H21N3O2S 9 Toxicological Information
Solubility:
To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
No data available.
p p p p DMSO
2 Handling and Storage
10 Regulary Information
3 Stability and Reactivity
11Disposal Considerations
CLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)
STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,
skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Please store the product under the recommended conditions in Certificate of Analysis.
11 Disposal Considerations 4 Hazards Identification
12 Transport Information
5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.
As specific country, federal, state and local environmental
regulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.
Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.
MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.
5 First Aid
13 Other Information
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d t
INHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin with
soap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes with
copious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.
6 Fire Fighting Measures
handling or from contact with the above product.
EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.
SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes only
Medchemexpress LLC
to prevent contact with skin and eyes.
18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。